CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis. Additionally, Cumberland recently received FDA clearance to proceed directly to a Phase II study for patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease.
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website at www.cumberlandpharma.com.
Overlake Medical Center & Clinics and MultiCare Health System announced today that they have signed an affiliation agreement emphasizing their joint long-term commitment to deliver the highest quality, most advanced health care to communities across...
Philadelphia, United States of America
7:30 a.m.
The Prime Minister will virtually attend the Artificial Intelligence Seoul Summit.
Closed to media
11:35 a.m.
The Prime Minister will meet with the President of Service Employees International Union...
Branch, the industry's leading linking and measurement partner for growth-focused teams, today announces the release of Branch Advanced Compliance, a premium solution that provides enhanced security, privacy and data measures for customers in heavily...
IGC Pharma, Inc ("IGC" or the "Company"), today announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.
During the conference, members of the IGC...
The Weinbach Group, a leading healthcare advertising agency, announced CitiMed, a multispecialty, fully integrated healthcare practice with five locations throughout Miami-Dade and Broward Counties, engaged the firm to handle marketing and...
Genesis + HOCL, the leading innovator in HOCL atomizing technology, is set to be featured on 'Great Day Washington' on WUSA, Channel 9 in Washington, DC. The segment will air today, Tuesday, May 21, at 3:00 pm EDT, coinciding with Clean Air Month...